Triple therapy shows promise against rare sarcomas
NCT ID NCT06128863
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tests a combination of two immunotherapy drugs (pembrolizumab and eftilagimod alpha) plus radiation before surgery for adults with soft tissue sarcoma. The goal is to see if this approach shrinks tumors more effectively. About 40 participants with high-risk, non-spread sarcomas will receive the treatment and then have surgery to remove the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, 00-738, Poland
Conditions
Explore the condition pages connected to this study.